Najit Technologies, Inc.
Najít Technologies is dedicated to the development of safe and effective vaccines against infectious diseases of global importance, with a focus on protecting vulnerable populations through innovative vaccine platforms like HydroVax. The company aims to address emerging and re-emerging infectious diseases, especially those affecting developing countries, by leveraging proprietary technologies to create safer, heat-stable, and immunologically effective vaccines.
Industries
Nr. of Employees
small (1-50)
Najit Technologies, Inc.
Beaverton, Oregon, United States, North America
Products
West Nile virus vaccine candidate (oxidation-inactivated, whole-virus)
An inactivated whole-virus West Nile vaccine produced using an oxidation-based inactivation approach; demonstrated immunogenicity in preclinical models and progressed to Phase I clinical testing.
Yellow fever vaccine candidate (inactivated, oxidation-based)
A next-generation inactivated yellow fever vaccine developed using oxidation-based inactivation intended to provide a safer alternative to live attenuated vaccines for vulnerable populations.
Chikungunya virus vaccine candidate (inactivated, oxidation-based)
An inactivated chikungunya vaccine developed using oxidation-based inactivation that demonstrated protection in animal models and has undergone cGMP manufacturing and Phase I testing.
Campylobacter vaccine candidate (inactivated, HydroVax-based)
An inactivated Campylobacter vaccine candidate developed using an oxidation-based approach; demonstrated 83% efficacy in a natural-exposure non-human primate model.
Universal influenza vaccine research (inactivated, epitope-preserving)
Research toward a universal influenza vaccine using inactivated virus particles with structurally intact HA and NA antigens to elicit broad and durable antiviral immunity.
West Nile virus vaccine candidate (oxidation-inactivated, whole-virus)
An inactivated whole-virus West Nile vaccine produced using an oxidation-based inactivation approach; demonstrated immunogenicity in preclinical models and progressed to Phase I clinical testing.
Yellow fever vaccine candidate (inactivated, oxidation-based)
A next-generation inactivated yellow fever vaccine developed using oxidation-based inactivation intended to provide a safer alternative to live attenuated vaccines for vulnerable populations.
Chikungunya virus vaccine candidate (inactivated, oxidation-based)
An inactivated chikungunya vaccine developed using oxidation-based inactivation that demonstrated protection in animal models and has undergone cGMP manufacturing and Phase I testing.
Campylobacter vaccine candidate (inactivated, HydroVax-based)
An inactivated Campylobacter vaccine candidate developed using an oxidation-based approach; demonstrated 83% efficacy in a natural-exposure non-human primate model.
Universal influenza vaccine research (inactivated, epitope-preserving)
Research toward a universal influenza vaccine using inactivated virus particles with structurally intact HA and NA antigens to elicit broad and durable antiviral immunity.
Services
Collaborative product co-development
Partnerships for co-developing vaccine candidates with organizations that have disease-area expertise.
Licensing and sublicensing of vaccine technology
Agreements for licensing technology and sublicensing rights to develop and commercialize vaccine products.
Collaborative product co-development
Partnerships for co-developing vaccine candidates with organizations that have disease-area expertise.
Licensing and sublicensing of vaccine technology
Agreements for licensing technology and sublicensing rights to develop and commercialize vaccine products.
Expertise Areas
- Vaccine platform development (oxidation-based inactivation)
- Inactivated viral and bacterial vaccine R&D
- Preclinical efficacy testing in animal models (including non-human primates)
- Phase I clinical trial execution (safety and immunogenicity)
Key Technologies
- Site-directed oxidation-based pathogen inactivation
- Hydrogen peroxide-based virus inactivation
- Polyatomic oxyanion-mediated epitope protection
- Inactivated whole-virus vaccine production